Therapeutic Areas

Adoptive Cell Therapy

• Chimeric antigen receptor (CAR) T-cell therapy - Adoptive cell therapies like CAR-T involve collection of immune cells from a patient followed by ex vivo manipulation and/or expansion and reinfusion, and are the foundations of immuno-oncology today after showing success in the treatment of hematologic malignancies (MSD, Luminex, PCR, Flow Cytometry, ELISpot)
• Customized, specific assessment of hematologic malignancies.

Viracor Offerings:

• Platforms for immunoassay ligand binding assays
• Detection/quantification of gene expressions performed by qPCR.
• Vector copy number (VCN)
• ELISPOT analysis is for the measurement of specific T- or B cell responses.
• Flow cytometry for analysis of cellular targets including T cell activation, and cytokine release syndrome (CRS)

Additional genomics capabilities for clinical immunotherapy studies:

• Predictive biomarker assays (whole exome or RNA sequencing)
• qPCR or microarray-based RNA expression assays
• qPCR and ddPCR for replication-competent lentivirus (RCL) and replication-competent retrovirus (RCR) testing, and measuring gene persistence
• Gene expression profiles for detecting and characterizing mutations/biomarkers in cancer cells
• Comprehensive targeted NGS panels or tumor profiling assays to detect known and emerging biomarkers, and measure tumor mutational burden